Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population.

Arq Bras Cardiol · 2017 · PMC5644206 · PMID 28977052

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a strong trendp = 0.08so close (0.05 < p ≤ 0.1)

In the PEPCAD-II trial, there was, in contrast to our findings, a strong trend towards lower rates of MACE in the DEB group compared to paclitaxel-eluting stent (9% versus 22%, respectively; p = 0.08). 21 However, in addition to being compared to first-generation DES, there were only 5 total deaths in the PEPCAD-II trial, suggesting again a population at lower overall risk th

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.